GTBP - התחייבויות לטווח ארוך של החברה GT Biopharma Inc

GT Biopharma, Inc. (GTBP) is developing innovative TriKE drugs for the targeted destruction of tumors, aiming for global leadership in the oncohematology segment through the expansion of clinical trials. This chart illustrates the price action of the asset with a debt metric of 0.00. The business's financial stability relies on medical test results and external investments, as it currently has no proprietary sales.

Asset managers require an accurate assessment of an issuer's long-term solvency to minimize risks. This indicator captures total liabilities with maturities exceeding one year, determining the level of debt load. Analyzing the firm's long-term borrowings allows for the identification of hidden liquidity threats through loan service dynamics. For GT Biopharma, Inc. (GTBP), such investments are critical for developing costly cold chains. This ensures the preservation of oncology drugs and stable business margins.